Free Trial
→ Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad)

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 6 of 15

Slide 6
Back to 5
Continue to 7
 
Back to 5
Continue to 7
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.9
Ratings Breakdown
6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$144.50 (44.8% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
10/17/2024BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$160.00 ➝ $156.00
10/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/8/2024BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$170.00 ➝ $160.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
6/25/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$163.00 ➝ $163.00
Slide 6
Back to 5
Continue to 7
 

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

Register For The Webinar To Discover

More From MarketBeat
Top "Sleeping Giant" Crypto In The Market Now
Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...
Crypto 101 Media | Sponsored
20 Stocks Analysts Won't Stop Upgrading
As you know, a single upgrade from a Wall Street analyst probably won't be a major game-changer for any single...
MarketBeat
Missed Nvidia? Watch this ASAP
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...
Brownstone Research | Sponsored
7 Undervalued Growth Stocks Ready for Reversal
Traders and investors are digesting what a 50-basis point (0.50%) cut in interest rates means for stocks. If y...
MarketBeat
Is Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...
Paradigm Press | Sponsored
7 Commodity Stocks To Prepare You for the Coming Supercycle
The election of Donald Trump as President of the United States is likely to significantly impact commodity pri...
MarketBeat